Drug Profile
Research programme: ERK inhibitors - Astex Pharmaceuticals
Latest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Astex Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Extracellular signal-regulated MAP kinase inhibitors; Mitogen activated protein kinase 3 inhibitors; Mitogen-activated protein kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for preclinical development in Cancer in United Kingdom (PO)
- 26 Oct 2017 Preclinical trials in Cancer in United Kingdom (PO)
- 26 Oct 2017 Interim pharmacodynamics data from preclinicals tudies in cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017 (AACR-NCI-EORTC-2017)